To read the full story
Related Article
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
July 24, 2023
- China Envoy Says Spying Allegations of Astellas Employee Becoming Certain
April 10, 2023
- Japanese Embassy Official Meets Astellas Employee Detained in China
April 5, 2023
- Japanese Foreign Minister Demands Release of Man Detained in China
April 3, 2023
- Japan’s Foreign Minister Likely to Visit China Soon, Demand Citizen’s Release
March 29, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
BUSINESS
- Taisho Seeks Japan Nod for Insomnia Med Vornorexant
September 13, 2024
- Opdivo-Yervoy Filed for 1st Line Use in MSI-H Colorectal Cancer in Japan
September 13, 2024
- Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
- IBM, Kobe Biomedical Cluster Join Hands to Expedite Clinical Trials with AI
September 12, 2024
- Oral COVID Drugs Prescribed to 180,000 Patients: August Data
September 12, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…